Jennison Associates’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-6,977
| Closed | -$418K | – | 749 |
|
|
2019
Q4 | $418K | Sell |
6,977
-577,416
| -99% | -$21.7M | ﹤0.01% | 603 |
|
|
2019
Q3 | $16.4M | Sell |
584,393
-30,985
| -5% | -$1.06M | 0.02% | 338 |
|
|
2019
Q2 | $23.3M | Sell |
615,378
-731,592
| -54% | -$28.1M | 0.02% | 323 |
|
|
2019
Q1 | $52.6M | Buy |
1,346,970
+322,279
| +31% | +$9.24M | 0.05% | 215 |
|
|
2018
Q4 | $21.8M | Sell |
1,024,691
-3,977
| -0.4% | -$103K | 0.02% | 341 |
|
|
2018
Q3 | $40.7M | Buy |
1,028,668
+8,112
| +0.8% | +$302K | 0.04% | 281 |
|
|
2018
Q2 | $39M | Buy |
1,020,556
+17,877
| +2% | +$662K | 0.04% | 300 |
|
|
2018
Q1 | $30.1M | Buy |
1,002,679
+148,857
| +17% | +$5.04M | 0.03% | 338 |
|
|
2017
Q4 | $26.7M | Buy |
853,822
+9,762
| +1% | +$268K | 0.03% | 359 |
|
|
2017
Q3 | $23.6M | Sell |
844,060
-2,213
| -0.3% | -$48.1K | 0.02% | 382 |
|
|
2017
Q2 | $16.2M | Buy |
846,273
+546,617
| +182% | +$8.73M | 0.02% | 431 |
|
|
2017
Q1 | $5.11M | Hold |
299,656
| – | – | 0.01% | 511 |
|
|
2016
Q4 | $5.47M | Buy |
299,656
+1,070
| +0.4% | +$18.5K | 0.01% | 509 |
|
|
2016
Q3 | $5.32M | Buy |
+298,586
| New | +$4.53M | 0.01% | 508 |
|
Jennison Associates's BOLD Position: Q1 2020 in Review
Jennison Associates sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 6,977 shares — an estimated $418K sold.
Jennison Associates first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $52.6M in Q1 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Jennison Associates reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Jennison Associates sold 6,977 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $418K.
- Jennison Associates first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Jennison Associates's Audentes Therapeutics, Inc position peaked at $52.6M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Jennison Associates's 13F filing for Q1 2020, filed 6 May 2020.